Resistance of Omicron subvariants BA.2.75.2, BA.4.6, and BQ.1.1 to neutralizing antibodies

Convergent evolution of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 lineages has led to the emergence of several new subvariants, including BA.2.75.2, BA.4.6. and BQ.1.1. The subvariant BQ.1.1 became predominant in many countries in December 2022. The subvariants carry an additional and often redundant set of mutations in the spike, likely responsible for increased transmissibility and immune evasion. Here, we established a viral amplification procedure to easily isolate Omicron strains. We examined their sensitivity to 6 therapeutic monoclonal antibodies (mAbs) and to 72 sera from Pfizer BNT162b2-vaccinated individuals, with or without BA.1/BA.2 or BA.5 breakthrough infection. Ronapreve (Casirivimab and…

• S
  Sanofi
• AN
  Agence Nationale de la Recherche

  Awards: PROTEO-SARS-CoV-2, ANR-10-LABX-77, 10-LABX-62-IBEID, 10-INSB-04-01, ANR-10-INSB-04-01, ANR-16-CONV-0005, ANR-10-LABX-62-IBEID, ANR-10, ANR-10-INSB-04, ANR-10-LABX-62
• IN
  Institut National de la Santé et de la Recherche Médicale

  Awards: ANR-10-LABX-77, ANR-10-LABX-62-IBEID
• FP
  Fondation pour la Recherche Médicale

  Awards: ANR-10-LABX-62-IBEID, PROTEO-SARS-CoV-2, ANR-16-CONV-0005, EQU202003010172
• FW
  Fonds Wetenschappelijk Onderzoek

  Award: G0H4420N
• UD
  Universitat de València
• KL
  KU Leuven

  Award: 3M170314
• CN
  Centre National de la Recherche Scientifique

  Awards: UMR3569, 10-LABX-62-IBEID, ANR-10-LABX-62
• IN
  Institut National de la Recherche Agronomique
• UP
  Université Paris-Saclay
• VR
  Vlaamse regering
• SU
  Sorbonne Université
• UD
  Université de Paris
• NI
  National Institutes of Health

  Awards: COVID-19, U01AI151758